TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Infant eczema symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: validity and reliability of ESCOMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KCCQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FACIT-Pal score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HADS-depression score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Technical failure rate of CTP acquisition/processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median additional time to acquire CTP after non-contrast CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door-to-needle times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of proven bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: NIH at 7 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical area of glow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in non-nicotine biomarkers of exposure (BoEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Blood COHb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of FS Spiromax to Seretide Accuhaler
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexibility of the back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Work-related musculoskeletal disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma noradrenaline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Passing score on the Arthroscopic Surgery Skill Evaluation Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of pressure pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in area and ILI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congruence between clinical and MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times for faces showing positive emotions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times during the working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Oxy‐Hb concentration changes in the PFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: early urinary dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Medication adherence at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean weight of sputum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean/median total cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean glucose reduction during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean percentage time in range for 24h after resistance training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma C(max) of etamicastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma AUC(0‐∞) of etamicastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma C(max) of BIA 5‐961
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: motility of semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: viscosity of semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Accuracy of tunnel placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Precision of tunnel placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic accuracy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hospital admission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in length of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean maximum plasma concentration (C(max)) of praziquantel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from 0 to 24 hours (AUC(0-24)) of praziquantel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocational recovery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to first analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total P acnes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clindamycin-resistant P acnes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in gene expression related to atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of repeated ABR examinations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of repeated analysis using sedative drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-traumatic stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: thoughts that life was not worth living
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintenance of healed EO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic evidence of joint damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of episiotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of epidural anesthesia for pain relief in labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: screening cost per endoscopy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost for detecting one esophageal cancer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost for detecting one early-stage esophageal cancer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of Candida species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response to electrical stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily pKt/V
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean daily pCCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative inflammation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of anterior capsule opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Organization Test (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dizziness Handicap Inventory (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vertigo Symptom Scale (VSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC(0-72 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of deep-tissue infection
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity in detecting recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity in detecting recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in detecting recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sealant penetration scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean subjective signs and symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent reduction in the revised AFS endometriosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean bone mineral density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in UPSA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of pulmonary morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative life quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CD19+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NCMC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibition of proliferation of human MC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain score at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with moderate to severe pain (VAS >4) within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of surgical wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stability of intraoperative blood pressure and heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: postoperative sulfentanil requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge of asthma symptoms and inhaler use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: abdominal fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intervals between PROM and onset of uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: post-30 day first rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: new onset diabetes mellitus (NODM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: antigenetic von Willebrand factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: sphincter preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: P1 latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: N1 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality within 60 days
Endpoint domain: Mortality/survival
Primary endpoint: Walking ability recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to community living
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: LTSR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(tau,ss))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum concentration (C(min,ss))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shorter sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Higher FR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher BMI‐SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall perceptions of TVC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical activity adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in softness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in aminoterminal propeptide of type I procollagen (PINP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in bone-specific alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast cancer risk associated with HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Conjunctival inflammation
Endpoint domain: Adverse events/effects
Primary endpoint: Dry eyes
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in KOOS subscale measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: taste alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interval to taste alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular Density (MVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular Endothelial Growth Factor (VEGF) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: hypoxemia with walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: breathlessness during walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined clinical and endoscopic remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marks awarded in SOE compared to COE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amounts of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical cure (CC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological cure (MC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in HAM-D score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z score of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Z score of body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BAP level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DPD levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent change in log FGF23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adjusted rates of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted rates of cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large very low-density lipoprotein particle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: length of first stage of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of caesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: satisfaction with labour care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean CGI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of dystonia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h Urinary Protein (UP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in core depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF‐36 Physical component scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Insulin resistance reduction (HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Days on medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Eating disorder cognitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric symptom severity scores
Endpoint domain: Adverse events/effects
Primary endpoint: Pairwise agreement for differentiation of nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FA values for the genu of corpus callosum (ΔFAgenu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of allergic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to preliminary diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative duration of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Pain score on VAS at 6 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of scrotal edema
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative muscle strength of the iliopsoas muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bubble formation after cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-dive FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CIBIC-plus (Clinician's Interview-Based Impression of Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the risk of heart failure or death
Endpoint domain: Mortality/survival
Primary endpoint: Perceived exertion during testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid-base levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tolerance of solutions
Endpoint domain: Adverse events/effects
Primary endpoint: naloxone-precipitated opioid withdrawal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification rate of sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAR AUC 0-3h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS AUC 0-3h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease from baseline of summary score for congestion/stuffiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PCSS at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PCSS at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ongoing MTBI symptoms (PCSS > 20) at 2 and 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes